At a glance
- Originator AstraZeneca
- Class Antineoplastics; Hormones
- Mechanism of Action Estrogen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 05 Feb 1996 Discontinued-Preclinical for Cancer in United Kingdom (Unknown route)